Optimer Pharmaceuticals was founded in 1998 and is based in San Diego, California. Optimer Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing anti-infective products worldwide. The company develops products that treat gastrointestinal infections and related diseases. Its two late-stage anti-infective product candidates include Fidaxomicin, the lead product candidate and an antibiotic that is in second Phase III registration trial for the treatment of clostridium difficile-infections; and Prulifloxacin, a prodrug in the fluoroquinolone class of antibiotics, which completed second Phase III trials for the treatment of infectious diarrhea in travelers. It also develops OP-1068/CEM-101, an antibiotic for the treatment of upper and lower respiratory tract infections; OPT-88, a disease-modifying intra-articular, or within the cavity of a joint, therapy for osteoarthritis; OPT-822, a carbohydrate-based cancer immunotherapy for the treatment of metastatic breast cancer; and an OPopS drug discovery platform. The company has a collaborative research and development, and license agreement with Cempra Pharmaceuticals, Inc. to discover, develop, and commercialize drugs based on macrolide and ketolide compounds.

BioGenex Laboratories, Inc. company was founded in 1981 and is based in San Ramon, California. BioGenex Laboratories Inc provides automated systems that streamline operations in molecular and cellular pathology laboratories. It offers Xmatrx Dx, an automated staining system that includes detection kits, primary antibodies, probes, reagents, and consumables for immunohistochemistry (IHC), in situ hybridization (ISH) and special stains (SS); i6000 that is an automated staining system designed for clinical diagnostics and research laboratories; EZ-Retriever System v.2, a microwave-based time and temperature controlled system designed to unmask the antigens on the formalin-fixed paraffin-embedded (FFPE) tissue sections; i500 Integrated Labeling System, a portable barcode solution, which creates barcode and text labeling for histology and cytology slides; and Xmatrx Rx, a biomarker assay development and analysis system that offers possibilities for translational and clinical research. The company also provides antibodies, antigen retrieval, ancillary reagents, detection systems, special stains, and tissue controls. In addition, it provides DNA/RNA synthesis labeling reagents, phosphoramidite, and branching phosphoramidites. The company serves reference laboratories, hospital laboratories, cancer treatment centers, university medical centers, group practices, and drug discovery laboratories in pharmaceutical and biotechnology firms, as well as oligonucleotide houses and academic institutions. BioGenex Laboratories Inc markets its products through distributors in Africa, Asia, Australia, Europe, the Middle East, North America, and South America.

Purdue Pharma L.P. company specializes in developing, manufacturing, and marketing sustained-release and long-acting treatments for chronic and severe pain. Its opioid drugs for pain relief include controlled-release analgesics OxyContin (a version of oxycodone), Ryzolt (tramadol), and morphine drug MS Contin. The company continues to develop and commercialize new products through alliances with such companies as Transcept and Labopharm. Purdue also sells a number of non-prescription products including topical antiseptic Betadine and the Colace and Senokot lines of laxatives. Purdue Pharma operates in the US.

Telik, Inc. company was founded in 1988 and is based in Palo Alto, California. Telik, Inc., a clinical stage drug development company, focuses on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. Telik company's advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the discovery of small molecule drug candidates.

AMAG Pharmaceuticals, Inc. company was founded in 1981 and is based in Lexington, Massachusetts. AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic iron compounds to treat anemia in the United States, Europe, and Japan. It also provides novel imaging agents to aid in the diagnosis of cancer and cardiovascular diseases. It offers Feraheme, an iron replacement therapeutic agent for the treatment of iron deficiency anemia and used as a diagnostic agent for vascular enhanced magnetic resonance imaging (MRI) to assess peripheral arterial disease; and GastroMARK used for delineating the bowel in MRI. AMAG Pharmaceuticals products also include Combidex, an investigational functional molecular imaging agent.

EMD Serono develops a potpourri of prescription pharmaceuticals used for the treatment of neurological, metabolic, and fertility disorders and diseases such as multiple sclerosis (MS), lupus, and HIV. The Massachusetts-based company conducts research and development programs in the US and markets products that include Gonal-f, Luveris, Ovidrel, Rebif, and Zorbtive in the US and Canada. The company has manufacturing and marketing agreements with other pharmaceutical firms, including Pfizer (MS) and CuraScript (fertility). EMD Serono is the North American operating subsidiary of Merck Serono S.A..

Integrated DNA Technologies (IDT) is there when you need some genetic materials in a pinch. The company supplies oligonucleotides (oligos), which are essentially short strands of DNA, to research and development entities. Oligos are used to develop new drugs, create diagnostic tests for genetic and infectious diseases, and develop agricultural products. IDT custom-makes the strands using chemical DNA synthesis machines that can create the oligos within a day after the company has received an order. Founded in 1987, IDT has offices in Australia, Belgium, Canada, Russia, and the US; it also has distributors in some 20 other countries in Africa, Asia, Europe, the Americas, and the Middle East.

FibroGen, Inc. company is focused on developing and commercializing treatments for fibrosis, anemia, diabetes, and cancer, as well as producing recombinant human collagens and synthetic gelatins. FibroGen has several products in clinical development, including: FG-3019, a monoclonal antibody that may treat a variety of conditions including diabetic nephropathy; FG-2216, an orally administered small molecule drug in development for the treatment of anemia; FG-5017, a recombinant version of human collagen; and FG-5009, a synthetic gelatin molecule designed to stabilize vaccines and biologics. The company commenced lab operations in 1995.

IS Pharma, formerly known as Maelor, is a UK-based drug and medical device company focused on products for the hospital market; it sells directly in the UK and uses distributors elsewhere. Among its products are Volpex, Haemopressin, and ISOplex, all critical care products used in surgery; Mysoline, an oral treatment for epilepsy; and Cryogesic and Aloxi, two cancer drugs. Maelor outlicenses some products outside its core focus areas to other firms, including its OptiFlo catheter, which is distributed by C.R. Bard. Previously limited primarily to the UK market, the firm bought Swiss drug firm Specialty European Pharma International in 2008, giving it a wider presence in Europe and in North America.

Labopharm Inc., a specialty pharmaceutical company, develops drugs by incorporating its proprietary controlled-release technologies. It offers once-daily formulation of the analgesic tramadol under the RYZOLT brand name for the treatment of severe chronic pain in adults. The company sells RYZOLT primarily in the United States, Europe, Canada, South Korea, and Australia. Labopharm's products in pipeline include once-daily formulation of trazodone, a serotonin antagonist reuptake inhibitor for the treatment of depressive disorder. Its product candidates in clinical development based on Contramid platform comprise twice-daily formulation of tramadol plus acetaminophen to address acute pain; and Abuse Deterrent Platform to provide safer medications through resistance to the uncontrolled release of the active ingredient after actions, such as breaking, chewing, crushing and heating, or consumption with alcohol. Its product candidates in clinical development based on the Polymeric Nano-Delivery System platform comprise lipid-and preservative-free formulation of the intravenous anaesthetic agent propofol; and SN-38, which is the active metabolite in the prescribed intravenous colon cancer drug irinotecan.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.